The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
Study Type
OBSERVATIONAL
Enrollment
1,500
patients on palbociclib combination treatment
Pfizer Sweden
Sollentuna, Sweden
RECRUITINGProportion of patients on treatment
Proportion of patients who have not discontinued treatment will be assessed at various timepoints (Time Frame: treatment start date through end of study \[assessed up to 48 months\])
Time frame: 01 January 2017 until 30 September 2020
Proportion of patients alive
Proportion of patients alive on palbociclib combination treatment at different points in time (Time Frame: treatment start date through end of study \[assessed up to 48 months\])
Time frame: 01 January 2017 until 30 September 2020
Describe the demographic and clinical characteristics of the patient population receiving palbociclib combination treatment
Time frame: 01 January 2017 until 30 September 2020
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.